253 related articles for article (PubMed ID: 19017824)
1. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.
Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E
Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824
[TBL] [Abstract][Full Text] [Related]
2. Livedoid skin reaction probably due to imatinib therapy.
Martínez-González MC; del Pozo J; Yebra-Pimentel MT; Pérez M; Almagro M; Fonseca E
Ann Pharmacother; 2007 Jan; 41(1):148-52. PubMed ID: 17190842
[TBL] [Abstract][Full Text] [Related]
3. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Chang H; Shih LY
Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
[TBL] [Abstract][Full Text] [Related]
4. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
5. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
[TBL] [Abstract][Full Text] [Related]
6. [Imatinib-induced DRESS].
Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
[TBL] [Abstract][Full Text] [Related]
7. Syndrome of inappropriate antidiuretic hormone secretion induced by a single dose of oral cyclophosphamide.
Gilbar PJ; Richmond J; Wood J; Sullivan A
Ann Pharmacother; 2012 Sep; 46(9):e23. PubMed ID: 22911342
[TBL] [Abstract][Full Text] [Related]
8. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract][Full Text] [Related]
9. A case of non-SIADH-induced hyponatremia in depression after treatment with reboxetine.
Koelkebeck K; Domschke K; Zwanzger P; Hetzel G; Lang D; Arolt V
World J Biol Psychiatry; 2009; 10(4 Pt 2):609-11. PubMed ID: 17965988
[TBL] [Abstract][Full Text] [Related]
10. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.
Mahapatra M; Mishra P; Kumar R
Ann Hematol; 2007 Jul; 86(7):537-8. PubMed ID: 17287945
[No Abstract] [Full Text] [Related]
11. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
[TBL] [Abstract][Full Text] [Related]
12. The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypopharyngeal cancer.
Kusuki M; Iguchi H; Nakamura A; Nishiura H; Kanazawa A; Yamane H
Acta Otolaryngol Suppl; 2004 Oct; (554):74-7. PubMed ID: 15513517
[TBL] [Abstract][Full Text] [Related]
13. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
14. Irreversible sensorineural hearing loss due to Imatinib.
Attili VS; Bapsy PP; Anupama G; Lokanatha D
Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
16. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing.
Tanvetyanon T; Nand S
Ann Pharmacother; 2003 Dec; 37(12):1818-20. PubMed ID: 14632593
[TBL] [Abstract][Full Text] [Related]
17. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
[TBL] [Abstract][Full Text] [Related]
18. Imatinib-induced pseudoporphyria.
Timmer-de Mik L; Kardaun SH; Kramer MH; Hayes DP; Bousema MT
Clin Exp Dermatol; 2009 Aug; 34(6):705-7. PubMed ID: 19077095
[TBL] [Abstract][Full Text] [Related]
19. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.
Foringer JR; Verani RR; Tjia VM; Finkel KW; Samuels JA; Guntupalli JS
Ann Pharmacother; 2005 Dec; 39(12):2136-8. PubMed ID: 16288076
[TBL] [Abstract][Full Text] [Related]
20. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.
Severino G; Chillotti C; De Lisa R; Del Zompo M; Ardau R
Ann Pharmacother; 2005 Jan; 39(1):162-4. PubMed ID: 15546944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
